Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ROSCURE-O2

Financiado

Development and evaluation of Radical Oxygen Species (ROS)-responsive drug deliv...

Development and evaluation of Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases. The evolving landscape of medical research demands innovative breakthroughs to enhance disease treatments. Smart drug delivery systems (DDS) are at the forefront of these innovations, offering precise drug release while combatting... ver más

31/08/2026

CSIC

165K€

Presupuesto del proyecto: 165K€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-17

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100%

1 Participantes

CSIC

165.31K€ | Lider

Proyectos interesantes

PID2021-127531NB-I00 CATALIZADORES ANTIOXIDANTES SINTETICOS: EVALUACION DE SU POT... 115K€ Cerrado

HypoRuLight Hypoxic Tumour Models for Photoactivatable Ruthenium based C... 150K€ Cerrado

RTC-2017-6109-1 Desarrollo preclínico de nuevos triterpenos hidroxamatos (TR... 197K€ Cerrado

CTQ2014-56833-R IDENTIFICACION DE NUEVOS QUIMIOTIPOS CON PROPIEDADES ANTIOXI... 98K€ Cerrado

PID2021-124932OB-I00 BIOTECNOLOGIA Y BIOFISICA DE MEMBRANAS PARA DESARROLLAR TERA... 303K€ Cerrado

SAF2012-37344-C03-01 DISEÑO Y SINTESIS DE NUEVAS MOLECULAS MODULADORAS DE DIANAS... 211K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 28 meses Fecha Inicio: 2024-04-17
Fecha Fin: 2026-08-31

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA...

TRL 2-3 | 552M€

Presupuesto del proyecto 165K€

Descripción del proyecto The evolving landscape of medical research demands innovative breakthroughs to enhance disease treatments. Smart drug delivery systems (DDS) are at the forefront of these innovations, offering precise drug release while combatting oxidative stress and harmful species. ROSCURE-O2 (Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases), is a pioneering proposal focusing on engineering ROS-responsive DDS with anti-inflammatory and anti-hypoxia properties.Inflammation profoundly affects global health, contributing to various skin and wound conditions, including radiation-induced skin injuries (RISI). RISI arises from healthy cells' exposure to ionizing radiation used in cancer radiotherapy, leading to issues ranging from mild skin reactions to severe burns, ulcers, infections, and necrosis, impacting the quality of life for over 95% of radiotherapy patients. ROSCURE-O2 aims to develop innovative treatments for inflammatory conditions by targeting ROS and hypoxia precisely. The hypothesis posits that multifunctional DDS can (1) scavenge ROS, (2) selectively release anti-inflammatory drugs, and (3) deliver oxygen in ROS-rich environments, thus preventing and curing inflammatory diseases. This triple therapeutic approach seeks to overcome the limitations of conventional treatments. Within ROSCURE-O2 the development of a Smart DDS platform that can synergistically address ROS and hypoxia. This involves polymeric DDS with ROS-responsive properties, provided by sulfur-based chemistries and/or antioxidant crosslinkers and the incorporation of oxygen-releasing and ROS-scavenging nanoparticles, like Cerium Oxide. These nanoparticles can be combined with anti-inflammatory active pharmaceutical ingredients to increase treatment efficacy and reduce costs. ROSCURE-O2's outcomes have the potential to advance our understanding of ROS-responsive drug delivery and tissue regeneration through oxygen delivery.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores